CIM
ESPR icon

Cambria Investment Management’s Esperion Therapeutics ESPR Stock Holding History

Cambria Investment Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-163
Closed -$13K – 327
2015
Q2 		$13K Hold
163
– – ﹤0.01% 223
2015
Q1 		$15K Buy
+163
New +$10.5K ﹤0.01% 167

Other funds holding ESPR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BB Biotech
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Discovery Capital Management
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Cambria Investment Management's ESPR Position: Q3 2015 in Review

Cambria Investment Management sold out of Esperion Therapeutics (ESPR) in Q3 2015, closing a stake of 163 shares — an estimated $13K sold.

Cambria Investment Management first reported a position in ESPR in Q1 2015 and held it in 2 quarters. The position peaked at $15K in Q1 2015. 121 funds tracked by Wall St. Rank hold ESPR as of Q3 2015.

  • Cambria Investment Management reported no remaining Esperion Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Cambria Investment Management sold 163 Esperion Therapeutics shares in Q3 2015, an estimated $13K.
  • Cambria Investment Management first reported a position in Esperion Therapeutics in Q1 2015 and held it in 2 quarters.
  • Cambria Investment Management's Esperion Therapeutics position peaked at $15K in Q1 2015.
  • 121 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2015.

Based on Cambria Investment Management's 13F filing for Q3 2015, filed 2 Nov 2015.